The National Institutes of Health (NIH) has unveiled a clinical trials network focused on evaluating various cancer screening technologies. This work is in support of Cancer Moonshot, "investigating how to identify cancers earlier, when they may be easier to treat."
To read more about this research network, click here.
A new model created by Melanoma Institute Australia (MIA), further described and discussed in a recent issue of the Journal of Clinical Oncology, has been shown to "predict recurrence-free survival and overall survival in patients with a primary cutaneous melanoma considerably better" than what is described in cancer staging manuals. Study authors further concluded that the MIA model can be used in daily practice without the need to conduct sentinel node biopsy, even for high-risk patients.
To learn more about the MIA model, click here.
Study mentioned:
Varey AHR, Li I, El Sharouni M-A, et al. Predicting Recurrence-Free and Overall Survival for Patients With Stage II Melanoma: The MIA Calculator. JCO; Published online 5 February 2024. DOI: https://doi.org/10.1200/JCO.23.01020
The National Coalition for Cancer Survivorship (NCCS) has recently created a webinar, presented by Jill Meter-Lippert, dental hygienist and founder of Side Effect Support, discussing "current evidence or oral-systemic links with various types of cancer." The presentation discusses a partnership between oncologists and dental practitioners, focusing on "oral hygiene modifications and product recommendations" to prevent, delay, or reduce complications from side effects following cancer treatments.
Click here to view the complete webinar.
